Speakers

2022 Speakers - 5th Annual TPD Summit

Discover what fresh new expert speakers and returning KOLs will be presenting at the 5th Annual Targeted Protein Degradation Summit in Boston this October.

PHARMA & INDUSTRY LEADERS
ACADEMIC LEADERS

PHARMA & INDUSTRY LEADERS

Arthur T. Sands

President & CEO

Nurix Therapeutics, Inc

Beth J. Hoffman

CEO

Origami Therapeutics, Inc.

Danette L. Daniels

VP, Protein Degrader Platform

Foghorn Therapeutics

Jared Gollob

CMO

Kymera Therapeutics

Leah Fung

CSO Biology

BioTheryx

Adam Gilbert

Executive Director & Head of Design & Synthesis Sciences, WRD&M

Pfizer

Effie Tozzo

CSO

Avilar Therapeutics

Markus Queisser

Scientific Director

GSK

Sharon Shechter

Director, Platform Integration

Roivant Discovery

Xinghai Li

CSO

Hinova Pharmaceuticals, Inc.

Bryce Allen

CEO

Differentiated Therapeutics

Jeffrey Simard

Director, Cell Pharmacology

C4 Therapeutics Inc

Jullian G. Jones

CBO

Monte Rosa Therapeutics

Lingling Shen

Associate Director - Data Science & Chemical Biology & Therapeutics Chemical Biology & Therapeutics

Novartis AG

Stefanie Schalm

Senior Director, Oncology

Kymera Therapeutics

Helai Mohammad

Head of Biology

Proteovant Therapeutics

Michael Pourdehnad

VP, Early Clinical Development, Hematology/Oncology & Cell Therapy

Bristol Myers Squibb

Nan Ji

CEO

PAQ Therapeutics

Simon Bailey

Executive VP, Drug Discovery

Plexium

Thomas M. Smith

Associate Director

Novartis Institutes for Biomedical Research

Ammar Adam

Senior Director & Head of in-vivo Pharmacology

Foghorn Therapeutics

Christine Jones

Senior Research Scientist

Arvinas

Daniela Santiesteban

Director, Targeted Protein Degradation

Salarius Pharmaceuticals

Sara Humphreys

Principal Scientist

Amgen

Silvia Buonamici

SVP, Drug Discovery

Monte Rosa Therapeutics

Gisele Nishiguchi

Principal - Lab Medicinal Chemistry

St. Jude Children's Research Hospital

Helen Trinh Pham

Senior Scientist II

Monte Rosa Therapeutics

Jaehyun Choi

CEO

EPD Biotherapeutics Inc.

Jennifer Johnston

CEO

Nysnobio

Shanique Alabi

Scientist I

Monte Rosa Therapeutics

Alice McDonald

Director - Translational Biology

Kymera Therapeutics

Jacqueline Kinyamu-Akunda

Senior Scientific Director, Nonclinical Safety

Janssen R&D

Michael Plewe

SVP Medicinal Chemistry

Cullgen Inc.

Ryan B. Rountree

senior Director, Pre-Clinical Pharmacology

Nurix Therapeutics, Inc

Scott Foster

Senior Scientist

Genentech

Aparajita Hoskote Chourasia

VP, Biology

Biotheryx

Gary T Choy

Co-Founder & CEO

f5 Therapeutics Incorporated

Hyunsun Jo

Founder & CEO

Pin Therapeutics

Jason Speake

VP Chemistry

Oerth Bio

Peter Park

CSO

Orum Therapeutics

Chris Hickey

Research Investigator

Arvinas

Kanae Gamo

CSO

FIMECS, Inc.

Robert McDonald

Senior Director, Platform Biology

Kymera Therapeutics

Stewart Fisher

CSO

C4 Therapeutics

Zhe Sha

Principal Scientist

UCB

Benedict Cross

CTO

PhoreMost Ltd

Matthew Calabrese

Senior Director & Head of Structural & Molecular Sciences

Pfizer

Mela Mulvihill

Director & Principal Scientist

Genentech

Pablo Gainza

Senior Scientist

Monte Rosa Therapeutics

Scott A. Kanner

Co-Founder & Head of Platform Development

Stablix

David C. Fry

Distinguished Research Leader

NJ Bio

Fredrik Rahm

Senior Project Advisor

Pelago Biosciences AB

Gael Nicolas

Senior Technical Sales Specialist

Refeyn

Michael Drummond

Scientific Applications Manager

Chemical Computing Group

Sofia Rodriguez

Research Analyst

Beacon Targeted Therapies

Angela Cacace

SVP of Neuroscience & Platform Biology

Arvinas

Bill Forrester

Global Co-Lead, TPD Initiative

Novartis

Christopher G. Nasveschuk

SVP, Chemistry

C4 Therapeutics

Karteek Kadimisetty

Director R&D

LifeSensors

Stuart Collinson

CEO & President

Coho Therapeutics

Henrik Daub

CSO

NEOsphere Biotechnologies GmbH

Kristin Riching

Senior Research Scientist

Promega

Phil Chamberlain

Co-Founder, President, & CEO

Neomorph, Inc.

Volker Martin Schmiedel

Principal Scientist

Boehringer Ingelheim RCV

Zuni Bassi

Principal Scientist II

Novartis

Chong-Hui Gu

Head of CMC

Foghorn Therapeutics

Jack Yan

VP of cryoEM

Biortus

Larry Jin

COO

Biortus

Natasa Zamurovic

Ribrioux Strategy & Portfolio Director - Pre-Clinical Safety & Translational Medicine

Novartis

Robert Haigh

CEO

Outrun Therapeutics

Sam Shrivastava

Founder & CEO

Asha Therapeutics

ACADEMIC LEADERS

Daniel Nomura

Professor

University of California, Berkeley

Gisele Nishiguchi

Principal - Lab Medicinal Chemistry

St. Jude Children's Research Hospital

Marina Konopleva

Professor, Department of Leukemia

MD Anderson Cancer Center

Taosheng Chen

Director of High Throughput Bioscience Center

St. Jude Children’s Research Hospital

William Farnaby

Principal Investigator

University of Dundee

Daohong Zhou

Professor and Director of the UTHSA Center for Innovative Drug Discovery

University of Texas Health Science Center at San Antonio (UTHSA)

Geoff Dann

Scientist, Center for Protein Degradation

Dana-Farber Cancer Institute

Jun Qi

Assistant Professor

Dana-Farber Cancer Institute

Xiaoyu Zhang

Assistant Professor

Northwestern University

Zoran Rankovic

Director, Chemistry Centers

St. Jude Children's Research Hospital

Amit Choudhary

Assistant Professor of Medicine

Harvard Medical School

Jim Wells

Professor

UCSF

Jin Wang

Professor

Baylor College of Medicine

Ketan D Patel

Associate Professor of Pharmaceutics

St. John’s University, NY

Mariella Filbin

Assistant Professor, Dana-Farber Cancer Institute

Harvard Medical School

Max Jan

Assistant Professor

Massachusetts General Hospital

VIEW AGENDA